Phillips 2002.

Methods	DESIGN Description: Randomized, placebo‐controlled, parallel, flexible dose, 1 week single blind placebo run‐in BLINDING Participants: Unclear Assessors: Yes Administrators: Yes ALLOCATION CONCEALMENT Method: clinician kept code RANDOMISATION Method: computer generated urn procedure
Participants	SAMPLE Description: 67 DSM‐IV BDD, 68.7% female, average age: 32.1 years, average duration of illness: 14.5 years, 64.2% MDD, baseline severity on BDD‐YBOCS: 31.5 (fluoxetine) 30.8 (placebo) SCREENING Primary diagnosis: BDD‐DM Comorbidity: SCID‐P; SCID‐PD
Interventions	Description: fluoxetine (20‐80mg/d; mean dose: 77.7 mg/d) vs placebo (20‐80mg/d; mean dose: 76 mg/d) x 12 weeks
Outcomes	Primary outcomes: BDD‐YBOCS, Secondary outcomes: CGI‐I, BDD‐CGI, BDD‐NIMH,BABS, HAM‐D, BPRS, SOFAS, GAF Data estimation: LOCF
Notes	INDUSTRY SUPPORT Industry funded: No Medication provided by industry: Yes Any of the authors work for industry: Yes ADDITIONAL INFORMATION Drop‐out rates: 0 on fluoxetine and placebo Quality rating score: 39 3 patients in the fluoxetine and placebo groups received ongoing psychotherapy (not CBT)
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate